The Trendlines (SGX:42T) subsidiary, Vensica Medical, received approval from the U.S. Food and Drug Administration (FDA) to initiate Phase 2 clinical trials for its VixE drug delivery system, according to a Monday filing with the Singapore Exchange.
Shares of the medical and other services company were up nearly 5% in Tuesday trading.
The needle-free delivery system is being developed for the treatment of overactive bladder, with the phase 2 study expected to conduct trials across around 210 patients in the U.S. and Europe.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments